Product ID: SQMIG35H2165
Global Plasma Fractionation Market Size, Share, Growth Analysis, By Product(Albumin, Immunoglobulins), By Method(Centrifugation, Depth Filtration), By Application(Neurology, Hematology), By End Use(Hospitals & Clinics, Clinical Research and Others) - Industry Forecast 2024-2031
Report ID:
SQMIG35H2165 |
Region:
Global |
Published Date: April, 2024
Pages:
219
|
Tables:
119 |
Figures:
77
Global Plasma Fractionation Market Dynamics
Global Plasma Fractionation Market Drivers
Growing Aging Population
- The aging population is another major driver of the plasma fractionation market. As people age, they are more likely to develop chronic diseases and require medical treatments, including plasma-derived products.
Respiratory illnesses and AATD are becoming more prevalent
- Protease inhibitors like alpha-1-antitrypsin have been increasingly popular in recent years for the treatment of hepatic and lung conditions such cirrhosis, fibrosis, and inflammation of the liver. Undiagnosed and persistent, alpha-1-antitrypsin deficiency (AATD) is a hereditary metabolic condition. In the US, it causes 2-3% of emphysema cases. Alpha-1-antitrypsin deficiency causes pan-lobular emphysema to develop early in smokers and non-smokers, while aberrant alpha-1-antitrypsin buildup in the liver causes illnesses. AATD happens everywhere, but the prevalence varies by region. Chronic obstructive pulmonary disease (COPD), which also includes emphysema and chronic bronchitis, is referred to as this condition. A large number of instances of COPD are linked to severe AATD. The prevalence of the PI*ZZ Alpha-1 Antitrypsin genotype in people with COPD was reported to be roughly 50% in Europe, 37% in America, 9% in Asia, 3% in Australasia, and 1% in Africa, according to a published by Elsevier B.V. in July 2023. In persons over 40, the estimated crude prevalence of COPD was 13.51% in the United States, 12.45% in Europe, 13.22% in Africa, 11.70% in Asia, and 11.86% in Australasia. Prevalence was found to be much lower in parts of Asia and Africa, but significantly greater in Europe, the USA, Canada, New Zealand, and Australia.
- The number of persons receiving treatments for AATD and emphysema is anticipated to rise as a result of the increasing frequency of these diseases and advancements in diagnostic methods like CT scanning. In turn, this will increase demand for protease inhibitors like alpha-1-antitrypsin and support the market growth for plasma fractionation as a whole.
Global Plasma Fractionation Market Restraints
High Cost of Plasma Fractionation Products
- The high cost of plasma fractionation products is a major restraint on market growth. These products are expensive to manufacture, which can make them unaffordable for some patients and healthcare systems.
Recombinant substitutes' impact on the market
-
Companies in this market segment should benefit financially from recent approvals for recombinant factors such AFSTYLA (CSL), VONVENDI (Takeda/Shire), and Kovaltry (Bayer). Standard half-life products and extended half-life products are the two groups of recombinant factor products that are currently offered. The first group of recombinant factors remain in the body for the same amount of time as factor VIII or factor IX found in nature. Extended half-life products, on the other hand, have been changed to last longer in the body than conventional half-life products. Recombinant factors VIII and IX have become more popular in industrialized nations as alternatives to plasma-derived factors VIII and IX in the treatment of bleeding disorders, according to the results of the World Federation of Hemophilia's (WFH) 2020 Annual Global Survey. Recombinant factors, on the other hand, are now being used more frequently in nations like Brazil, India, and Russia. This tendency is anticipated to place certain restrictions on the development of plasma-derived coagulation factors, which will have an impact on the market's overall growth.
Global Plasma Fractionation Market Report Snapshots
Want to customize this report?
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATION
USA (+1) 351-333-4748
